Literature DB >> 2177039

Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole.

V Vuddhakul1, G T Mai, J G McCormack, W K Seow, Y H Thong.   

Abstract

Itraconazole and fluconazole are triazole compounds recently licensed for the therapy of systemic fungal infections. At 10 micrograms/ml concentrations, itraconazole was found to suppress neutrophil chemotaxis, random movement, deoxyglucose uptake and hexose-monophosphate shunt activity to the same extent as ketoconazole, an older generation azole antifungal. Itraconazole was also found to suppress mitogen-induced lymphocyte transformation to the same extent as ketoconazole at concentrations as low as 1 microgram/ml. By contrast, significant inhibition of both neutrophil and lymphocyte functions was not observed with fluconazole at concentrations as high as 50 micrograms/ml. These results suggest that fluconazole may be less immunotoxic than itraconazole, and may be more suitable for use in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177039     DOI: 10.1016/0192-0561(90)90101-r

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  8 in total

1.  Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes.

Authors:  T Vago; G Baldi; D Colombo; M Barbareschi; G Norbiato; F Dallegri; M Bevilacqua
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 2.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

3.  Impact of Antifungal Compounds on Viability and Anti-Aspergillus Activity of Human Natural Killer Cells.

Authors:  Stanislaw Schmidt; Ralf Schubert; Lars Tramsen; Thomas Lehrnbecher
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro.

Authors:  Fedja Farowski; Oliver A Cornely; Pia Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 5.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

6.  Effect of fluconazole on phagocytic response of polymorphonuclear leukocytes in a rat model of acute sepsis.

Authors:  Haseeb Ahmad Khan
Journal:  Mediators Inflamm       Date:  2005-02-24       Impact factor: 4.711

7.  Empyema in a woman with cystic fibrosis: a cautionary tale.

Authors:  Anne Coates; Oren Schaefer; Karl Uy; Brian P O'Sullivan
Journal:  Case Rep Pulmonol       Date:  2013-03-05

8.  Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.

Authors:  Thomas Lehrnbecher; Stanislaw Schmidt; Lars Tramsen; Thomas Klingebiel
Journal:  Front Oncol       Date:  2013-02-07       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.